Recursion is a clinical-stage TechBio company that utilizes a synchronized combination of hardware, software, and data to industrialize drug discovery, leveraging over 60 petabytes of biological and chemical data. The platform enables rapid profiling of gene and compound relationships, addressing the inefficiencies in traditional drug development processes.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Traditional drug discovery processes are inefficient due to the complexity of biological systems and the difficulty in rapidly profiling gene and compound relationships. This leads to lengthy development times and high costs in bringing new treatments to market.
Solution
Recursion is a TechBio company that has built a platform to industrialize drug discovery by creating virtuous cycles of learning around datasets. The company leverages a synchronized combination of hardware, software, and data, including over 60 petabytes of biological and chemical data, to rapidly profile gene and compound relationships. This approach allows for the creation of scalable and relatable data, enabling a next-generation biopharmaceutical company focused on decoding biology to radically improve lives. The platform aims to reshape the traditional drug discovery funnel, addressing broad therapeutic areas through internal development and partnerships.
Target Audience
Recursion's primary customers are biopharmaceutical companies and research institutions seeking to accelerate drug discovery and development through advanced technology and large-scale data analysis.
Features
- High-throughput experimentation: Up to 2.2 million wet lab experiments per week profiling genes and compounds.
- Scalable cell type production: Capability to produce over 50 cell types at scale, including over 1 trillion hiPSC-derived neuronal cells.
- Extensive data profiling: Over 6 trillion gene and compound relationships profiled.
- Advanced computing infrastructure: Top 500 supercomputer (BioHive-1) across any industry.
- Recursion OS: A synchronized combination of hardware, software, and data for drug discovery.